European Medicines Agency approves efficacy of inflammatory intestinal biologics

Business Agency, April 8 (Xinhua) -- The European Medicines Agency (EMA) Committee on Human Medicine products (CHMP) has a positive endorsement of Entyvio (vedolizumab), a biological agent it has submitted for the treatment of moderate to severe active ulcerative colitis or Crohn's disease in adults, the Osaka,japan-based Takeda saidIf CHMP's opinion is formally adopted by the European Commission, the biologics will be approved for listing in the 28 EU member states as well as Norway, Iceland and Liechtensteinulcerative colitis and Crohn's disease are two of the most common inflammatory bowel diseases, with more than 4 million patients worldwide, including about 2.2 million in EuropeUlcerative colitis and Crohn's disease are characterized by gastrointestinal inflammation, and the most common symptoms include abdominal discomfort, diarrhea, blood stool, weight loss, etc., the cause of which is still unclearvedolizumab is a human-derived monoclonal antibody used in conventional treatment or for the treatment oftumor
necrosis factor alpha (TNF alpha) antagonists, weak response softened or intolerant ulcerative colitis and Crohn's diseasePaul Rutgeert, a member of the Royal Society of Physicians, said: "Most patients diagnosed with ulcerative colitis or Crohn's disease are young people who will be plagued throughout their lives by the weakness ofdisease
and the complex treatment of chronic diseases, and the development and progress of scientific research will provide physicians and patients with more treatment options"